IMPACT OF CHRONIC KIDNEY DISEASE ON LONG-TERM OUTCOMES IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION AND ALTERNATIVE ANTITHROMBOTIC TREATMENT STRATEGIES: A HORIZONS-AMI SUBSTUDY  by Saltzman, Adam J. et al.
E904
JACC April 5, 2011
Volume 57, Issue 14
  MYOCARDIAL ISCHEMIA AND INFARCTION 
IMPACT OF CHRONIC KIDNEY DISEASE ON LONG-TERM OUTCOMES IN ST-ELEVATION MYOCARDIAL 
INFARCTION PATIENTS TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION AND 
ALTERNATIVE ANTITHROMBOTIC TREATMENT STRATEGIES: A HORIZONS-AMI SUBSTUDY
ACC Oral Contributions
Ernest N. Morial Convention Center, Room 238
Monday, April 04, 2011, 2:15 p.m.-2:30 p.m.
Session Title: Unstable Ischemic Syndromes: Acute Therapy and Long-Term Outcomes
Abstract Category: 1. Myocardial Ischemia/Infarction—Basic
Presentation Number: 916-4
Authors: Adam J. Saltzman, Bimmer E. Claessen, Amar Narula, Giora Weisz, Bruce Brodie, Bernhard Witzenbichler, Giulio Guagliumi, Ran Kornowski, 
Dariusz Dudek, Alexandra J. Lansky, Eugenia Nikolsky, George D. Dangas, Gregg W. Stone, Roxana Mehran, Columbia University Medical Center, New 
York, NY, Cardiovascular Research Foundation, New York, NY
Objectives: To investigate the impact of chronic kidney disease (CKD) in patients undergoing primary percutaneous coronary intervention (PCI) for 
ST-elevation myocardial infarction (STEMI) on long term clinical outcomes.
Background:  CKD is associated with an increased risk of adverse ischemic and hemorrhagic events after primary PCI for STEMI.
Methods:  A total of 3,602 patients were randomized to receive bivalirudin monotherapy or heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) in 
the HORIZONS-AMI trial. Of 3,397 patients with baseline creatinine clearance data CKD, defined as a creatinine clearance <60ml/min, was present 
in 554 patients (16.3%). The primary endpoint was the occurrence of net adverse cardiac events (NACE, a composite of major bleeding, death, 
reinfarction, target vessel revascularization (TVR) for ischemia, or stroke) at 30 days, 1 year, and 3 years.
Results:  Compared to patients without CKD, patients with CKD had higher rates of NACE at 30 days (21.3% vs. 9.0%, p<0.01), 1 year (30.3% vs. 
14.4%, p<0.01), and 3 years (41.4% vs. 23.8%, p<0.0001). At 3 years, patients with CKD had higher rates of death (18.7% vs. 4.4%, p<0.0001), 
major bleeding (non-CABG related) (19.3% vs 6.7%, p<0.0001), and strokes (3.2% vs. 1.6%, p=0.01). Patients with CKD did not have significantly 
higher rates of reinfarction (8.7% vs. 6.8%, p=NS), TVR (14.6% vs. 13.9%, p=NS), or probable/definite stent thrombosis (4.2% vs. 4.4%, p=NS) 
compared to patients without CKD at 3 years. The use of bivalirudin monotherapy versus heparin plus a GPI in patients with CKD showed no 
difference in NACE (41.1% vs. 41.7%, p=NS), or major bleeding (19.0% vs 19.6%, p=NS) at 3 years. In patients without CKD, bivalirudin monotherapy 
demonstrated significantly less major bleeding (non-CABG related) at 3 years compared to heparin plus a GPI (5.0% vs. 8.5%, p=0.0003).
Conclusion: Patients with CKD presenting with STEMI and treated with primary PCI have significantly worse outcomes compared to patients without 
CKD. CKD confers ongoing long term risk for net adverse clinical events following a STEMI.
